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Abstract 
Mutations in CHCHD10 have recently been reported as a cause of amyotrophic lateral sclerosis (ALS) and 
frontotemporal dementia (FTD). To address the genetic contribution of CHCHD10 to ALS we have screened a cohort 
of 425 UK ALS+/-FTD patients and 576 local controls in all coding exons of CHCHD10 by Sanger sequencing. We 
identified a previously reported Pro34Ser variant that was also present in neurologically healthy controls (p=0.58). 
Our results suggest that CHCHD10 is not a primary cause of ALS in UK cases.   
 
1. Introduction 
Amyotrophic lateral sclerosis (ALS) is an adult-onset neurodegenerative disease characterised by lower and upper 
motor neuron degeneration. Approximately 5-10% of ALS cases are familial (FALS) with the remainder presenting in 
a sporadic manner (SALS). Mutations in four major genes, SOD1, TARDBP, FUS and the intronic C9orf72 GGGGCC 
expansion account for approximately 50% of FALS. A recent report by Bannwarth et al. (2014) described a novel 
p.Ser59Leu (c.176C>T) mutation in CHCHD10 accounting for ALS and frontotemporal dementia (FTD). Subsequent 
independent screenings have also confirmed a putative role of CHCHD10 in a broad range of neurodegenerative 
diseases (Auranen et al., 2015; Johnson et al., 2014; Kurzwelly et al., 2015; Penttila et al., 2015; Zhang et al., 2015) 
(Supplementary Table 1). Here we report the first mutation screening of CHCHD10 in a UK cohort of familial and 
sporadic patients.  
2. Methods 
All 4 coding exons of CHCHD10 (NM_213720.2) were amplified by PCR and products directly sequenced with an 
ABI3130 (Applied Biosystems, Warrington, UK) (Supplementary Information).  
 
3. Results 
Analysis of an existing in-house cohort of UK FALS exomes revealed poor coverage (only 24.8% of samples met the 
minimum read depth ie. 8x) across exon 2 of CHCHD10 that is a hotspot for reported mutations. We therefore Sanger 
sequenced all exons of CHCHD10 in 163 FALS, 262 SALS and 576 healthy controls to ensure complete coverage of 
the gene. We identified the previously described p.Pro34Ser (c.100C>T) variant in 1 FALS (0.61%), 4 SALS (1.53%) 
and 8 controls (1.39%). One of the sporadic cases also carried the C9orf72 hexanucleotide expansion. Further SNP 
genotyping of position 100 in additional UK controls detected the minor allele, thymine, in 3/640 (0.31%) individuals. 
In line with Zhang et al. (2015) and Dobson-Stone et al. (2015), our screening results identified that the P34S 
frequency was non-significant in ALS cases versus controls (ALS/FTD n=5/425, 1.2% vs controls n=11/1,216, 0.82%) 
(p=0.58, 2-tailed Fischer’s exact test). Additionally, several other CHCHD10 variants were identified, however none 
were predicted to be pathogenic as they were either found only in controls, or were insufficiently rare in ExAC 
(Supplementary Table 2). None of the changes were predicted by Netgene2 
(http://www.cbs.dtu.dk/services/NetGene2/) to alter splicing. 
 
4. Discussion 
Our study failed to identify any disease-relevant variants, suggesting that mutations in CHCHD10 are not a common 
cause in UK ALS/FTD patients. The Pro34Ser variant was initially identified in two unrelated French FTD-ALS 
individuals (Chaussenot et al., 2014) and one Italian sporadic case (Ronchi et al., 2015). However in an Australian 
cohort of FTD and/or dementia patients (n=370), seven cases as well as nine aged controls (n=807) were found to 
carry the Pro34Ser change, suggesting that it is non-contributory to disease (p=0.290) (Dobson-Stone et al., 2015). 
Although this variant is absent in dbSNP (http://www.ncbi.nlm.nih.gov/SNP/) and EVS 
(http://evs.gs.washington.edu/EVS/), it is found nine times in the Non-Finnish European subset of the Exome 
Aggregation Consortium data at a frequency of 0.60% (n=1,508) (ExAC, http://exac.broadinstitute.org/). It is worth 
noting that the coverage of exon 2 at a read depth of at least 10x is relatively low (47.10%) with only 8.88% of 
samples achieving this threshold at Pro34 (ExAC release 1) potentially due to the GC-rich nature of this region (77.3% 
GC-content). The low coverage from next generation sequencing suggests that the true frequency of variants in 
controls may indeed be higher, as reflected by our Sanger sequencing data. Low coverage of exome sequencing reads 
from public databases is a note of caution when interpreting newly identified variants.  
 
To date, there has been an absence of published in-vitro studies investigating the functional impact of ALS-associated 
CHCHD10 mutations with the exception of the Ser59Leu change. Based on impact prediction tools and conservation 
of the codon, the Pro34Ser variant is predicted to influence the protein’s stability and/or protein-protein interactions 
(Chaussenot et al., 2014). One sporadic case from our cohort carried both a C9orf72 hexanucleotide repeat expansion 
and a Pro34Ser change as seen by Dobson-Stone et al. (2015). Several studies have reported double mutations in ALS 
or FTD associated genes, suggesting an oligogenic model requiring multiple ‘hits’ to manifest disease (King et al., 
2013; van Blitterswijk et al., 2013; van Blitterswijk et al., 2012). Together, these results suggest that the Pro34Ser 
variant is not pathogenic as the primary cause of disease, and its potential role as a susceptibility allele may be 
questionable. Functional investigation is essential to critically assess the contribution of CHCHD10 as a causative 
gene in ALS pathobiology as well as other neurodegenerative phenotypes. 
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